Business Wire

SAB Biotherapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of SAB-185 for the Treatment and Prevention of COVID-19

SIOUX FALLS, S.D.--(BUSINESS WIRE)--SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, ...
Nasdaq

SAB BIO Reports Positive Phase 1 Trial Results for SAB-142 in Type 1 Diabetes, Supporting Advancement to Phase 2b Development

SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
Nasdaq

SAB BIO Reports Q1 2025 Financial Results and Progress on SAB-142 for Type 1 Diabetes Treatment

SAB BIO, a clinical-stage biopharmaceutical company focused on developing immunotherapy for type 1 diabetes (T1D), announced its financial results for Q1 2025, highlighting substantial progress in its ...